Non-coding rna peptide antigens for cancer vaccines, therapeutics, and diagnostics
AssigneeCalviri, Inc.
InventorStephen Albert Johnston
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of identifying ncRNA neoantigens for diagnosing, treating, and preventing cancer. Also disclosed are methods and compositions for administering identified ncRNA neoantigens for the treatment and prevention of cancer.
Claims117
A method of identifying one or more ncRNA peptides (ncRNAPs) that are immunogenic, cancer-specific, and/or shared across cancers, comprising:
- a) contacting a ncRNA peptide array comprising a plurality of ncRNAPs with a first biological sample obtained from a first individual known to have a cancer,
- b) measuring binding of the first biological sample to the ncRNA peptide array,
- c) contacting the same type of ncRNA peptide array with a second biological sample obtained from a second individual,
- d) measuring binding of the second biological sample to the ncRNA peptide array,
- e) comparing the binding of the two biological samples to the ncRNA peptide array, and
- f) identifying one or more ncRNAPs that are immunogenic, cancer-specific, and/or shared across cancers.
A method of measuring an immune response to a plurality of ncRNA peptides, the method comprising:
- a) contacting a biological sample with an ncRNA peptide array comprising a plurality of ncRNA peptides,
- b) measuring binding of the biological sample to the ncRNA peptide array.
An array comprising a plurality of ncRNA peptides.
A method of detecting cancer in a subject, the method comprising:
- a) obtaining a biological sample from a subject,
- b) contacting the biological sample with an array comprising a plurality of ncRNAPs;
- c) measuring binding of the biological sample to the plurality of ncRNAPs;
- and
- d) analyzing the binding to predict whether the subject has cancer.
A method of predicting the response of a subject with cancer to an immunotherapy, comprising
- a) obtaining a biological sample from a subject with cancer,
- b) contacting the biological sample to an array comprising a plurality of ncRNAPs, and
- c) measuring binding of the biological sample to the plurality of ncRNAPs.
The method of 46, wherein analyzing the binding comprises comparing the binding of the biological sample to binding of another subject who responded positively to immunotherapy or experienced an adverse immune response in response to immunotherapy.
A vaccine composition comprising one or more ncRNA peptides.
A method of designing a cancer vaccine, the method comprising:
- a) identifying one or more ncRNAPs or one or more nucleic acids encoding ncRNAPs that are immunogenic, and
- b) preparing a vaccine comprising one or more ncRNAPs or one or more nucleic acids encoding ncRNAPs that are immunogenic.
The method of 63, further comprising determining a nucleic acid sequence of said ncRNAPs that are immunogenic to identify one or more nucleic acids encoding ncRNAPs that are immunogenic.
A method of treating or preventing cancer, comprising administering a vaccine comprising a) one or more ncRNA peptides or b) a nucleic acid sequence encoding one or more ncRNA peptides.
A method of treating a subject in need of treatment for a cancer, the method comprising:
- a) obtaining a biological sample from the subject;
- b) identifying one or more ncRNA peptides that are immunoreactive with a biological sample from the subject in a first population of ncRNA peptides;
- c) preparing a vaccine composition comprising a second population of ncRNA peptides comprising one or more peptides identified in step b) or a nucleic acid sequence encoding the second population of peptides;
- and
- d) administering an effective amount of the vaccine composition to the subject, thereby treating the cancer.
A method of treating or preventing cancer, comprising administering a therapeutic molecule designed to bind an ncRNAP.
A method of producing a therapeutic or preventative antibody specific for cancer of interest, comprising:
- a) contacting one or more biological samples obtained from one or more subjects identified as having the cancer of interest to an array comprising ncRNA peptides produced by one or more tumors;
- b) detecting antibodies which bind to the ncRNA peptides;
- c) selecting one or more ncRNA peptides that are immunoreactive with the antibodies;
- and
- d) preparing an antibody composition against the selected ncRNA peptides for the cancer of interest.
Dependencies are inferred from the claim text.